Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (291-300 of 306) with videos related to

Pageof 31
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 26, 2011
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virusYasuji Arase, Fumitaka Suzuki, Mariko Kobayashi, et al.
The American Journal of Gastroenterology|February 22, 2022
Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate PhaseTai-Chung Tseng, Tetsuya Hosaka, Chun-Jen Liu, et al.
Journal of Medical Virology|January 21, 2010
Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virusYasuji Arase, Fumitaka Suzuki, Yoshiyuki Suzuki, et al.
Hepatology (Baltimore, Md.)|March 20, 2025
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patientsTai-Chung Tseng, Tetsuya Hosaka, Mei-Hung Pan, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2020
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver diseaseYorinari Ochiai, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer|June 24, 2026
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup AnalysisMasatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, et al.
Oncology|November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib TreatmentDaiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer|January 14, 2021
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
The Lancet. Gastroenterology & Hepatology|May 16, 2020
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysisQing Ye, Biyao Zou, Yee Hui Yeo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 20, 2011
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patientsYasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, et al.
Pageof 31

Showing results (291-300 of 306) with videos related to

Sort By:
Pageof 31
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 26, 2011
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virusYasuji Arase, Fumitaka Suzuki, Mariko Kobayashi, et al.
The American Journal of Gastroenterology|February 22, 2022
Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate PhaseTai-Chung Tseng, Tetsuya Hosaka, Chun-Jen Liu, et al.
Journal of Medical Virology|January 21, 2010
Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virusYasuji Arase, Fumitaka Suzuki, Yoshiyuki Suzuki, et al.
Hepatology (Baltimore, Md.)|March 20, 2025
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patientsTai-Chung Tseng, Tetsuya Hosaka, Mei-Hung Pan, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2020
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver diseaseYorinari Ochiai, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer|June 24, 2026
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup AnalysisMasatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, et al.
Oncology|November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib TreatmentDaiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer|January 14, 2021
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
The Lancet. Gastroenterology & Hepatology|May 16, 2020
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysisQing Ye, Biyao Zou, Yee Hui Yeo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 20, 2011
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patientsYasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, et al.
Pageof 31